$ENDP it comes down to if you think this global company, who IPO’d in 1997, and has never had a reverse split, a $96 ATH, and currently has 3000 global employees, $654M sales Q1 2022 and $2.7B annual, $9B assets, huge OTC approved product pipeline, two lab subsidiaries with 12 locations in US/CA/India, a $90M US gov contract to scale Michigan lab for Vaccines and therapeutics, 86% institutional ownership, multiple lawsuit wins saving $1B in payments, new contracts with Quoin Pharm who just went 350% in the last week, Is going to delist. If you don’t believe they will delist, the Chaoter 11, in the worst case, is actually a catalyst.
View original message